News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xenogen Corporation (XGEN) Expands Product Line With Introduction Of New Optical Imaging System


3/31/2006 11:25:22 AM

ALAMEDA, Calif., March 31 /PRNewswire-FirstCall/ -- Xenogen Corporation announced today the launch of its IVIS Lumina(TM) Imaging System, an affordable, value-oriented optical imaging system that provides quantitative fluorescent and bioluminescent imaging capabilities. The IVIS Lumina System adds to Xenogen's expanding platform of IVIS systems, including the IVIS 3D System commercially launched in September 2005.

In line with the U.S. Food and Drug Administration's Critical Path Initiative, companies and research institutions are focusing on improving pre-clinical research. Xenogen's sophisticated optical imaging technology is designed to enable researchers to visualize, track and understand biological processes in living animals, non-invasively and in real time. The result can provide more accurate, predictable data that helps to improve the success rate of drug discovery and development and significantly reduce the cost and time to market for new therapies. Now this technology is offered at a more affordable price.

Xenogen's IVIS Lumina System was developed with principal investigator labs and academic institutions in mind because they require a pre-clinical imaging system that provides high-quality images at a more affordable price. In turn, the IVIS Lumina System is designed to provide ease of use, flexibility and high sensitivity for both in vitro and in vivo fluorescent and bioluminescent imaging.

"With the IVIS Lumina System, we want to give researchers the opportunity to purchase an IVIS system designed to generate high-quality data at an affordable price," said Pamela R. Contag, Ph.D., president of Xenogen Corporation. "The IVIS Lumina System allows researchers to affordably utilize Xenogen's advanced technology for drug discovery and development."

While the IVIS Lumina System is ideal for first-time customers, it also allows companies and research institutions that already own IVIS imaging systems to purchase additional imaging systems. Without a large expenditure, Xenogen believes the purchase of these supplemental systems can improve existing customers' efficiency and productivity.

Xenogen also announced the opening of a Web Store, which current and interested customers can access through the company's Website, www.xenogen.com. The online store offers Xenogen's Biological Solutions, including accessories for the company's IVIS imaging systems, software, training and service plans, reagents and transgenic services.

About Xenogen Corporation

Xenogen Corporation is a leading biotechnology company offering an integrated suite of optical real-time in vivo imaging and genetic modification technologies that can help expedite drug discovery and development and significantly reduce the cost and time to market for new therapies. Xenogen's VivoVision(TM) Systems non-invasively illuminate and monitor biological processes within living mammals, at the molecular level, in real time. The technology provides higher quality in vivo data earlier in the drug discovery and development process. VivoVision(TM) Solutions improve discovery and pre-clinical research in multiple therapeutic areas. VivoVision(TM) Biosciences represents more than 15 years of experience in the creation and characterization of animal models, including genetic modifications, comprehensive phenotyping, compound profiling and custom design and production of light producing cells, microorganisms and animals.

More information is available at www.xenogen.com.

NOTE: Xenogen(R), Living Image(R), Lumina(TM), VivoVision(TM) and IVIS(R) are trademarks of Xenogen Corporation.

Forward-Looking Statements

This press release contains forward-looking statements regarding the performance, adoption, intended uses and benefits of Xenogen's IVIS Lumina Imaging System, other imaging products and technologies. These forward-looking statements are based on Xenogen's current expectations, estimates and assumptions and are subject to many risks, uncertainties and unknown future events that could cause actual results to differ materially. Actual performance, adoption, intended uses and benefits of Xenogen's IVIS Lumina Imaging System, other imaging products and technologies may differ materially from those set forth in this release due to the risks and uncertainties inherent in Xenogen's business, including, without limitation: use and acceptance of Xenogen's products and technologies by pharmaceutical, biotechnology, biomedical and chemical companies; Xenogen's ability to continue to deliver its products on a timely basis; Xenogen's ability to enforce its intellectual property rights or operate without infringing or misappropriating the proprietary rights of others; products, services or technologies introduced by competing companies; and other risk factors set forth in Xenogen's filings with the Securities and Exchange Commission. For a discussion of these and other factors that could impact the performance, adoption, intended uses and benefits of Xenogen's IVIS Lumina Imaging System, other imaging products and technologies and cause them to differ materially from those in the forward-looking statements, please refer to Xenogen's recent filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K for the year ended December 31, 2005 filed with the Securities and Exchange Commission on March 24, 2006. Xenogen is under no obligation to (and specifically disclaims any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link. Pamela R. Contag, Ph.D. http://profnet.prnewswire.com/ud_public.jsp?userid=513625 David W. Carter http://profnet.prnewswire.com/ud_public.jsp?userid=513851

Xenogen Corporation

CONTACT: investors, William A. Albright of Xenogen Corporation,+1-510-291-6100; or media, Kelly McKenna of Manning Selvage & Lee,+1-415-254-6239, or Kelly.mckenna@mslpr.com, for Xenogen Corporation


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES